Processing

Please wait...

PATENTSCOPE will be unavailable a few hours for maintenance reason on Tuesday 25.01.2022 at 9:00 AM CET
Settings

Settings

Goto Application

1. WO2022009081 - DRUG FOR USE AGAINST THE NOVEL CORONAVIRUS DISEASE, COVID-19

Publication Number WO/2022/009081
Publication Date 13.01.2022
International Application No. PCT/IB2021/056031
International Filing Date 06.07.2021
IPC
A61K 9/00 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
A61K 38/57 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
55Protease inhibitors
57from animals; from humans
A61P 11/00 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
11Drugs for disorders of the respiratory system
A61P 31/16 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
31Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
12Antivirals
14for RNA viruses
16for influenza or rhinoviruses
A61K 9/19 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
14Particulate form, e.g. powders
19lyophilised
Applicants
  • TORVALD RANTA FORETAGSJURIDIK AB [SE]/[SE]
Inventors
  • KHANYKOV, Alexandr Vladimirovich
Agents
  • KOTLOV, Dmitry Vladimirovich
Priority Data
63/048,39106.07.2020US
Publication Language English (en)
Filing Language English (EN)
Designated States
Title
(EN) DRUG FOR USE AGAINST THE NOVEL CORONAVIRUS DISEASE, COVID-19
(FR) MÉDICAMENT DESTINÉ À ÊTRE UTILISÉ CONTRE LA MALADIE DU NOUVEAU CORONAVIRUS, LA COVID-19
Abstract
(EN) The invention concerns a medicinal drug effective for the treatment of COVID-19 disease caused by the SARS-Cov-2 virus and preventing the development of its dangerous complications associated with pulmonary edema. For this purpose, a drug is proposed comprising aprotinin as a pharmaceutically active component in the form of a dry powder aerosol with a particle size of less than 1.0 μm. Such a drug provides the possibility of targeted delivery of aprotinin to the lower respiratory tract and alveoli, which makes it possible to influence both the etiology (due to the antiviral effect of aprotinin) and the pathogenesis of COVID-19 disease (due to the anti-inflammatory effect of aprotinin) directly in the focus of the pathologic pathway.
(FR) L'invention concerne un médicament efficace pour le traitement de la COVID-19 causée par le virus SARS-Cov-2 et empêchant le développement de ses complications dangereuses associées à un œdème pulmonaire. À cet effet, l'invention concerne un médicament comprenant de l'aprotinine en tant que composant pharmaceutiquement actif sous la forme d'un aérosol de poudre sèche ayant une taille de particule inférieure à 1,0 µm. Un tel médicament permet une administration ciblée d'aprotinine dans les voies respiratoires inférieures et les alvéoles, ce qui permet d'influencer à la fois l'étiologie (en raison de l'effet antiviral de l'aprotinine) et la pathogenèse de la COVID-19 (en raison de l'effet anti-inflammatoire de l'aprotinine) directement dans le foyer de la voie pathologique.
Latest bibliographic data on file with the International Bureau